Hodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
|
|
- Evangeline Holt
- 5 years ago
- Views:
Transcription
1 Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
2 Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve a complete response The ongoing challenges ~ 30% of patients relapse Optimal chemotherapy regimen ABVD vs.. Treatment of older patients Reduce toxicity of standard therapy More effective therapy for advanced stage and primary refractory and relapsed disease
3 CD30 Targeted Therapy Pivotal study in 102 patients with relapsed/refractory HL after ASCT -75% objective response rate with brentuximab vedotin -34% complete response rate Younes A, et al. J Clin Oncol. 2012;30(18):
4 PD-1 Immune Checkpoint Pathway Classical Hodgkin lymphoma (chl) is characterized by expression of PD-L1 and PD-L2 on malignant Reed Sternberg cells and on inflammatory cells in the tumor microenvironment PD-L1 expression in chl frequently occurs in the setting of genetic amplification of the 9p24.1 locus PD-L1 expression in chl Copy Gain Amplification PD-L1/L2 copy gains and amplification visible by FISH Chen BJ, et al. Clin Cancer Res. 2013;19(13): Ansell SM, et al. N Engl J Med. 2015;372(4): Ansell SM, et al. Blood. 2015;126: Abstract 583.
5 Hodgkin Lymphoma Front-Line Treatment Abstract 6: Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients With Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study Abstract 89: Sequential Brentuximab Vedotin Before and After Adriamycin,Vinblastine, and Dacarbazine (Bv-AVD) for Older Pts with Untreated Hodgkin Lymphoma (HL): Final Results from a Multicenter Phase II Study Abstract 651: Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (chl): Results from the Phase 2 Checkmate 205 Study Salvage Therapy Abstract 694: Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma Abstract 650: Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 Checkmate 205 Study Abstract 738: Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients With Relapsed/Refractory Hodgkin Lymphoma
6 Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients With Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study Abstract 6 Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman TA, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen RW, Ramchandren R, Zinzani PL, Cunningham D, Heo DS, Rosta A, Josephson N, Ruffner KL, Sachs J, Liu R, Jolin H, Hubner D, Radford JA
7 ECHELON-1: Open-Label, Global, Randomized, Phase III Study of a+avd Versus ABVD in Patients With Newly Diagnosed Advanced chl Connors J, et al. Blood. 2017;130: Abstract 6.
8 Disease Characteristics Comparable Between A+AVD and ABVD Connors J, et al. Blood. 2017;130: Abstract 6.
9 Modified PFS per Independent Review Connors J, et al. Blood. 2017;130: Abstract 6.
10 Summary of Subsequent Therapy Connors J, et al. Blood. 2017;130: Abstract 6.
11 Most Clinically Important Treatment-Emergent Adverse Events Incidence (Any Grade) 20% + Febrile Neutropenia Connors J, et al. Blood. 2017;130: Abstract 6.
12 Peripheral Neuropathy and Pulmonary Events Connors J, et al. Blood. 2017;130: Abstract 6.
13 Sequential Brentuximab Vedotin Before and After Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Pts With Untreated Hodgkin Lymphoma (HL): Final Results From a Multicenter Phase II Study Abstract 89 Evens AM, Advani RH, Fanale M, Smith SM, Jovanovic B, Helenowski I, Bociek G, Klein AK, Winter JN, Gordon LI, Hamlin PA
14 Elderly Hodgkin Disease/Lymphoma Defined: age 60 years Under-represented in clinical trials: <5%-10% (vs 15%-25% population) Outcomes disproportionately inferior to younger patients EFS and OS ~ 40-50% No standard treatment approach Evens AM, et al. Blood. 2017;130: Abstract 89.
15 Incorporation of Brentuximab Vedotin Into Front-Line Therapy PET1 and CT1 (Staging) BV x 2 cycles (1.8 mg/kg q 3 wks) AVD x 6 cycles BV consolidation (1.8 mg/kg q 3 wks x4) PET2 (first 22pts) CT + PET (all pts) Phase II investigator-initiated study Untreated advanced-stage elderly HD ( 60 yo) Participating institutions: Tufts, Northwestern, Univ of Chicago, UMass, Ohio State, MDACC, Stanford, Nebraska, and MSKCC Window (lead-in) study with brentuximab vedotin CGA (CIRS-G) and HRQL assessments Study of early FDG-PET Evens AM, et al. Blood. 2017;130: Abstract 89.
16 (N = 48) (N = 41) Results: Efficacy BV x 2 AVD x 3 AVD x 3 BV x 4 ORR 87% CR 30% (PET) ORR 98% CR 76% ORR 95% CR 90% ORR 95% CR 93% ITT (n = 48) after 6 AVD: ORR 88% and CR 81% Evens AM, et al. Blood. 2017;130: Abstract 89.
17 Survival: PFS and OS Evens AM, et al. Blood. 2017;130: Abstract Year PFS 85% and 2-year OS 94% (ITT)
18 Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (chl): Results From the Phase 2 CheckMate 205 Study Abstract 651 Ramchandren R, Fanale MA, Rueda A, Armand P, Trěný M, Feldman TA, Ansell SM, Provencio M, Jaeger U, Cohen JB, Savage KJ, Willenbacher W, Sacchi M, Sumbul A, Domenech ED
19 Ramchandren R, et al. Blood. 2017;130: Abstract 651. Study Design
20 Baseline Demographics and Clinical Characteristics Ramchandren R, et al. Blood. 2017;130: Abstract 651.
21 Ramchandren R, et al. Blood. 2017;130: Abstract 651. Treatment-Related AEs
22 Ramchandren R, et al. Blood. 2017;130: Abstract 651. Immune-Mediated AEs
23 Response by IRC and Investigator-ITT Ramchandren R, et al. Blood. 2017;130: Abstract 651.
24 Ramchandren R, et al. Blood. 2017;130: Abstract 651. Modified PFS per IRC
25 Nivolumab Treatment Beyond Investigator- Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study Abstract 650 Cohen JB, Engert A, Ansell SM, Younes A, Trneny M, Savage KJ, Ramchandren R, Collins G, Fanale MA, Armmand P, Zinzani PL, De Boer JP, Shipp MA, Santoro A, Timmerman JM, Sacchi M, Sy O, Kuruvilla J
26 Nivolumab for Relapsed Hodgkin Lymphoma Younes A, et al. Lancet Oncol. 2016;17(9): Fanale M, et al. ICML 2017 Cohen JB, et al. Blood. 2017;130: Abstract 650.
27 Cohen JB, et al. Blood. 2017;130: Abstract 650. Study Design
28 Phase II CheckMate 205 R/R chl Study Design Cohen JB, et al. Blood. 2017;130: Abstract 650.
29 70 of 105 (67%) patients with investigator-assessed disease progression were TBP Stable reductions in tumor burden were seen with continued treatment in patients TBP OS from first dose of study drug was 93% at 12 months for patients TBP Median time to next therapy was 8.8 months (vs 1.5 months for non-tbp) Nivolumab was well tolerated with an acceptable safety profile Cohen JB, et al. Blood. 2017;130: Abstract 650. Summary
30 Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma Abstract 649 Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH
31 Study Rationale BV activates the immune system and initiates an antitumor response through the induction of immunogenic cell death Nivolumab targets PD-1 and restores an effective antitumor response Herrera AF, et al. Blood. 2017;130: Abstract 649.
32 Methods Target enrollment: ~55 patients Patients were treated in 21-day cycles for up to 4 cycles (12 weeks) During Cycle 1, BV was administered on Day 1 and Nivo on Day 8 During Cycles 2-4, dosing of both drugs occurred on Day 1 of each cycle After completion of the Cycle 4 response assessment, patients were eligible to undergo ASCT Investigator assessment of lymphoma response and progression was per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson et al, 2014) Herrera AF, et al. Blood. 2017;130: Abstract 649.
33 Patient Characteristics and Disposition Herrera AF, et al. Blood. 2017;130: Abstract 649.
34 Herrera AF, et al. Blood. 2017;130: Abstract 649. Response
35 Brentuximab Vedotin + Nivolumab BV + Nivo was well tolerated 44% of patients experienced IRRs, 41% Gr 1-2, 3% Gr 3 <10% had potential iraes requiring steroids Treatment did not impact stem cell mobilization and stem cell collection: patients were able to proceed to ASCT uneventfully BV + Nivo treatment resulted in Increasing circulating T-cell numbers, and increase in adaptive immuneactivating cytokines and chemokines Increased ability of memory T-cells to mount an immune response Herrera AF, et al. Blood. 2017;130: Abstract 649.
36 Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients With Relapsed/Refractory Hodgkin Lymphoma Abstract 738 Chen RW, Palmer JM, Herrera AF, Stiller T, Armenian SH, Mei M, Popplewell L, Fueger A, Qasim I, Stiller T, Rosen ST, Forman SJ, Kwak LW
37 Study Schema Note: There is a safety lead-in portion using only 420 mg oral daily Chen R, et al. Blood. 2017;130: Abstract 738.
38 Patient Characteristics Characteristic, n (%) Phase II Patients [n = 13] 560 mg Ibrutinib Safety Lead-In Patients [n = 3] 420 mg Ibrutinib All patients [N = 16] Gender Female Male 5 (38) 8 (62) 2 (67) 1 (33) 7 (44) 9 (56) Age 33 (17-69) 33 (21-52) 33 (17-69) Stage at Diagnosis I-II III-IV 7 (54) 6 (46) 1 (33) 2 (67) 8 (50) 8 (50) B symptoms (at diagnosis) 6 (46) 3 (100) 9 (56) Prior Therapy ABVD BEACOPP R-CHOP IGEV BV ICE Clinical Trials PD1 inhibitors 12 (92) 3 (23) 1 (8) 1 (8) 1 (8) (100) (33) 3 (100) 2 (67) 3 (100) 3 (100) 15 (94) 3 (19) 1 (6) 2 (13) 4 (25) 2 (13) 3(19) 3 (19) Prior Radiation 3 (23) 0 3 (19) Status Prior to Treatment Progressive Disease Relapsed Disease Stable Disease 7 (54) 6 (46) 0 2 (67) 0 1 (33) 9 (56) 6 (38) 1 (6) Best Response to Induction Refractory Relapsed Chen R, et al. Blood. 2017;130: Abstract (38) 8 (62) 3 (100) 0 8 (50) 8 (50)
39 Efficacy Characteristic, n (%) Phase II Patients [n = 13] 560 mg Ibrutinib Safety Lead-In Patients [n = 3] 420 mg Ibrutinib All Patients [N = 16] Median Number of Cycles 5 (2-9) 2 (2-6) 4 (2-9) Best Response CR PR SD PD 6 (46) 5 (39) 2 (15) (33) 0 2 (67) 6 (37) 6 (37) 2 (13) 2 (13) Response Rate (PR/CR) 84.6% 33.3% 75.0% Safety lead-in allowed refractory BV pts Chen R, et al. Blood. 2017;130: Abstract 738.
40 Conclusions Front-line Treatment Brentuximab vedotin in combination with AVD Superior modified PFS G-CSF primary prophylaxis recommended for all patients Brentuximab vedotin incorporated sequentially before and after AVD feasible for older HL pts High CR rate (>90%) and overall well tolerated Nivolumab monotherapy followed by N-AVD well tolerated in patients with advanced stage chl Salvage Therapy Treatment with nivolumab beyond progression associated with long-term clinical benefit Active combinations in the R/R setting Brentuximab + Nivolumab ORR 83%, CR 62% Brentuximab + Ibrutinib ORR 84.6%, CR 46%
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationResponse Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy
Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationPresented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition; December 9 12, 2017; Atlanta, GA, USA
65 Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 25 Study Jonathon B. Cohen, 1 Andreas
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationTHERAPEUTIC ADVANCES IN HODGKIN AND T-CELL LYMPHOMAS
THERAPEUTIC ADVANCES IN HODGKIN AND T-CELL LYMPHOMAS Jakub Svoboda, MD UPDATE IN HEMATOLOGIC MALIGNANCIES with Proceedings from International Medical Meetings January 26, 2018 DISCLOSURES Jakub Svoboda
More informationTreatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center
Treatment Approaches in Relapsed/Refractory HL Brentuximab Vedo=n Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Thursday March 15, 2018: 10:15-10:30 am 1992 (Cell): Durkop
More informationHodgkin Lymphoma Nivolumab
New Drugs In Hematology Hodgkin Lymphoma Nivolumab Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:10-2:25 p.m immunotherapy modalities CAR T Cells
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationLINFOMA DI HODGKIN: RUOLO DEI CHECKPOINT INHIBITORS Armando Santoro
LINFOMA DI HODGKIN: RUOLO DEI CHECKPOINT INHIBITORS Armando Santoro CANCER IMMUNOTHERAPY TODAY TUMORS RESPONSIVE TO ANTI-PD1 OR ANTI-PD-L1 THERAPY! MELANOMA! RCC! NSCLC! UROTHELIAL CANCER! HEAD AND NECK
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationAdvances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
Wang et al. Journal of Hematology & Oncology (2018) 11:57 https://doi.org/10.1186/s13045-018-0601-9 REVIEW Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Yucai Wang 1, Grzegorz
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More informationHodgkin Lymphoma New Combo-Steps
New Drugs In Hematology Hodgkin Lymphoma New Combo-Steps Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:55-3:10 p.m Combinations with Immune Checkpoint
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Assess the efficacy and safety of brentuximab vedotin in investigational settings, such as in combination with AVD for patients with newly diagnosed HL, as consolidation
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationDoes BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationCheckpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD
Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Disclosures for Rob Laister Research Support Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationNew Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationBleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath
Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain
More informationWelcome and Introductions
Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationEmerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma
Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma Presented as a Live Webinar Thursday, October 26, 2017 1:00 2:00 p.m. ET On-demand Activity Live webinar recorded and archived to be
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin s Lymphoma
The new england journal of medicine Original Article Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin s Lymphoma J.M. Connors, W. Jurczak, D.J. Straus, S.M. Ansell, W.S. Kim, A. Gallamini,
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationBabis Andreadis, MD, MSCE Associate Professor of Medicine UCSF. Outline
ANCO Update in Lymphomas 2017 Babis Andreadis, MD, MSCE Associate Professor of Medicine UCSF Outline DLBCL Incorporating biomarkers in treatment choice CART19 therapy is here Mantle Cell Lymphoma: Induction
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin s Lymphoma
Original Article Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin s Lymphoma J.M. Connors, W. Jurczak, D.J. Straus, S.M. Ansell, W.S. Kim, A. Gallamini, A. Younes, S. Alekseev, Á. Illés,
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationLymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX
Best of ASCO 2011 Lymphoma Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX RCHOP21 in DLBCL (GELA LNH-98.5 Study) Survival Probability OS (N = 399)
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationEnd-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma
original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky
More informationWelcome & Introductions
Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin
More informationNew Antibody Based Therapies in Hematologic Malignancies
New Antibody Based Therapies in Hematologic Malignancies Leslie Popplewell, MD, FACP Associate Professor, City of Hope Department of Hematology and Hematopoietic Cell Transplantation Click to edit Master
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationFirst line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented
[Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationNovel Therapeutic Targets for Hodgkin Lymphoma
Hodgkin Lymphoma:...Therapeutic Biology Novel Therapeutic Targets for Hodgkin Lymphoma Antonello Pinto Hematology-Oncology and Stem Cell Transplantation Unit Department of Hematology National Cancer Institute,
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationNCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy
INDICATIONS FOR USE: INDICATION Brentuximab Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell transplant (ASCT) or Following at least two
More informationHodgkin Lymphom Aktuelle Strategien und Studien Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of Cologne
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Hodgkin Lymphom Aktuelle Strategien und Studien Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of Cologne Hodgkin
More informationNCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy
Brentuximab INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationGruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo
Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationNovel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma
HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma Craig Moskowitz Memorial Sloan-Kettering
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationExpert Perspective on ASH 2014: Lymphoma
Expert Perspective on ASH 2014: Lymphoma Myron S. Czuczman, MD Abstract The 2014 Annual Meeting and Exposition of the American Society of Hematology included many updates of previously presented studies,
More information